Purchase this article with an account.
T.K. Mundorf, R. Noecker, M. Earl; A Multicenter, Investigator–Masked, Randomized Comparison of the IOP–Lowering Efficacy of Bimatoprost 0.03% versus Travoprost 0.004% in African Americans with Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4502.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the IOP–lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in African Americans with glaucoma or ocular hypertension. Methods: Randomized, investigator–masked, multicenter, parallel–design clinical trial. After completing a washout of all ocular hypotensive agents, patients were randomized to bimatoprost QD (n=25) or travoprost QD (n=24) for 3 months. Study visits were at baseline and months 1, 2, and 3. The primary outcome measure was IOP. Results: There were no significant differences in baseline mean IOP (P=.146). Bimatoprost provided lower mean IOP than travoprost at the month 2 and 3 study visits. After 2 months of study medication, the mean IOP in the bimatoprost group was 17.7 mm Hg and 19.2 mm Hg in the travoprost group (P=.043). After 3 months, the mean IOP was 16.8 mm Hg in the bimatoprost group and 18.5 mm Hg in the travoprost group (P=.068). Mean IOP reductions ranged from 6.2 to 8.0 mm Hg (25.8% to 32.5%) with bimatoprost and from 5.9 to 6.9 mm Hg (23.2% to 27.6%) with travoprost. Conclusions: The findings of the present study suggest that bimatoprost is more effective than travoprost for IOP–lowering in African Americans with glaucoma or ocular hypertension.
This PDF is available to Subscribers Only